Nanoparticle cluster depolymerizes and removes amyloid fibrils for Alzheimer’s disease treatment

Nanomedicines for Alzheimer's disease: Therapies based on pathological mechanisms

“…This exposed the AAc groups, which produced electrophilic carbon ions that subsequently attacked nucleophilic lysine16 in pathological Aβ, eventually creating a VP‐Aβ complex (Figure 4C). [144] Interestingly, pathological Aβ can be transported from the CNS to the peripheral blood, [161] and the decrease in Aβ in the peripheral blood may in turn promote the efflux of Aβ from the brain. Therefore, it may be possible to clear pathological Aβ by bypassing the BBB.…”

“…Reproduced from Ref. [144] with permission. (D) (I) Preparation of erythrocyte membrane vesicles through hypotonic treatment.…”

Biomolecule-protected gold nanoclusters: synthesis and biomedical applications

“…Its pathology is characterized by extracellular amyloid plaques and intracellular neurogenic fiber tangles. 96,97 The first application of gold nanoclusters for AD was the use of in situ biosynthetic AuNCs for fluorescent labeling of affected sites in the Alzheimer's brain. 98 Then, Gao et al 99 explored the size effect of Au NPs and AuNCs in the inhibition of protein amyloidosis.…”

“…Its pathology is characterized by extracellular amyloid plaques and intracellular neurogenic fiber tangles. 96,97…”

Nonmonotonic relationship between the degradation of black phosphorus and its bioactivity in suppressing the centrosome polo-like kinase 1

“…5,6 These nanomaterials can elicit specific biological effects by interacting with particular biomolecules. 7,8 In comparison to many traditional molecular drugs, nanomaterials offer advantages such as greater transportation efficiency, lower effective doses, and reduced side effects. [9][10][11] Nevertheless, the clinical translation of nanomedicine remains challenging due to issues related to poor biocompatibility, slow biodegradation rate, and the substantial accumulation of nanomaterials in the body.…”